billHR1410Event Tuesday, February 18, 2025Analyzed

9/11 Responder and Survivor Health Funding Correction Act of 2025

Neutral
Impact2/10

Summary

HR1410 is an early-stage bill modifying the World Trade Center Health Program's funding formula and expanding mental health provider eligibility. It does not appropriate funds, has only been referred to committee, and has no direct near-term market impact on publicly traded healthcare companies.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

  • 1.HR1410 is pre-procedural with no appropriations and no near-term market impact
  • 2.No publicly traded company's revenue or competitive position is directly affected
  • 3.Recent 30-day rallies in HUM (+46.46%) and CNC (+69.75%) are unrelated to this bill

Market Implications

No actionable market implications from this bill. The WTCHP is a small, closed federal program with no derivative impact on large-cap managed care stocks. Recent price action in HUM and CNC reflects separate sector dynamics (likely related to Medicare Advantage rate announcements or broader healthcare policy), not HR1410. Investors should ignore this bill for portfolio decisions.

Full Analysis

HR1410 was introduced on February 18, 2025, and referred to the House Committee on Energy and Commerce. As of April 30, 2026, it remains in early legislative stages with only three procedural actions logged. The bill modifies the funding formula for the WTCHP for FY2026-FY2090 and expands licensed mental health provider categories for program evaluations, but it does not appropriate any new funds. Authorization without appropriation means no money flows unless a separate appropriations bill passes. The program itself is narrow in scope (9/11 responders and survivors) and does not create a new market or revenue stream for managed care organizations or other publicly traded healthcare companies. No direct causal chain exists between this bill and specific tickers like HUM or CNC, which have experienced significant price moves in April 2026 due to unrelated market factors (HUM up 46.46% in 30 days, CNC up 69.75%). The legislative path remains uncertain—no hearings, markups, or Senate companion action beyond introduction of S739. Given the early stage, zero appropriated funds, and narrow program scope, the market impact is negligible.

Market Impact Score

2/10
Minimal ImpactModerateMajor Market Event

Related Presidential Actions

Executive orders & memoranda affecting the same sectors or companies

Exec OrderApr 30, 2026

Promoting Efficiency, Accountability, and Performance in Federal Contracting

This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.

Exec OrderApr 18, 2026

Accelerating Medical Treatments for Serious Mental Illness

This executive order directs the FDA to prioritize review and facilitate 'Right to Try' access for psychedelic drugs, including ibogaine compounds, that have received Breakthrough Therapy designation for serious mental illnesses. It also allocates $50 million from HHS to support state programs advancing these treatments and mandates collaboration between HHS, FDA, VA, and the private sector to increase clinical trial participation and data sharing for these drugs. The Attorney General is further directed to expedite rescheduling reviews for approved Schedule I psychedelic substances.